7 September 2021
Geneva – In a joint declaration published on 6 September 2021, the G20 Health Ministers gathered in Rome, Italy reaffirmed their commitment to global solidarity, equity, and a multilateral approach towards ending the COVID-19 pandemic and strengthening the global pandemic preparedness mechanisms.
While supporting the global goal to vaccinate at least 40% of the population by the end of 2021, they highlighted the urgent need to share more doses and strengthen local and regional manufacturing capacity. The G20 Health Ministers reaffirmed their support to the work of key partners, including “WHO, Unitaid and the Medicines Patent Pool to facilitate voluntary technology transfers on mutually agreed terms, market shaping and increase local production capacities worldwide […]” (7).
“The current inequity in access to vaccines is behind the wave of death impacting hardest low- and middle-income countries,” said Charles Gore, Executive Director of the Medicines Patent Pool. “To address the global imbalance of manufacturing capacity for COVID-19 vaccines, MPP is working with many partners, including WHO on establishing the South African mRNA technology transfer hub that will allow for greater and more diversified vaccines manufacturing capability. We hope it will also contribute to strengthening African regional health security and respond more equitably to the current COVID-19 pandemic and future pandemics at global level.”
In their declaration, the G20 Health Ministers also recognised that non-communicable diseases such as cancer, cardiovascular disease, chronic respiratory disease, and diabetes may increase the risk of severity and death from COVID-19.
Access the Declaration of the G20 Health Ministers
More information on the South African mRNA technology transfer hub
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.